Ion channel contract research and drug discovery company Metrion Biosciences has moved to larger, custom-designed laboratory and office premises at Granta Park, Cambridge, UK which, the company says will allow it to significantly expand its range of services and cell lines. The 12,000 sq. ft (1,145 sq m) facility more than doubles Metrion Biosciences’ laboratory space and has been specifically designed to support the addition of GLP-compliant cardiac safety services and expanded cell biology facilities. The new laboratories provide significant additional capacity for ongoing and future client projects, and dedicated laboratory space for the introduction of 384-well format automated electrophysiology and enhanced liquid handling. Metrion has increased its headcount by 50% over the past three years and is actively recruiting to expand its team of expert laboratory scientists.

“Our new headquarters has been specifically designed to support Metrion’s ambitious business plan for global growth, with a particular focus on the USA in 2022,” commented Dr Andrew Southan, Metrion’s Chief Executive. “Following the recent appointment of Nick Foster as Chief Commercial Officer, the additional space will also allow for further growth of Metrion’s team of expert laboratory scientists. Metrion continues to build its reputation as a leading provider of drug discovery research services for ion channel targets across multiple therapeutic areas and I look forward to working with the team during this next phase of growth for our company.”